Biochemical comparison of four commercially available human α1-proteinase inhibitors for treatment of α1-antitrypsin deficiency. (November 2017)
- Record Type:
- Journal Article
- Title:
- Biochemical comparison of four commercially available human α1-proteinase inhibitors for treatment of α1-antitrypsin deficiency. (November 2017)
- Main Title:
- Biochemical comparison of four commercially available human α1-proteinase inhibitors for treatment of α1-antitrypsin deficiency
- Authors:
- Boerema, David J.
An, Bo
Gandhi, Ronak P.
Papineau, Randy
Regnier, Ed
Wilder, Anna
Molitor, Alexander
Tang, Andrew P.
Kee, Scott M. - Abstract:
- Abstract: Intravenous therapy with purified plasma-derived alpha1 -proteinase inhibitor (α1 -PI) concentrates is the only specific treatment for α1 -PI deficiency. For the therapy to be safe and efficacious, α1 -PI concentrates should be highly pure and contain high amounts of functional protein. This study compared the four plasma-derived α1 -PI products commercially available in Europe (Respreeza, Prolastin, Alfalastin, Trypsone) by biochemical methods with respect to function, purity, structure, and chemical modifications. Respreeza had the highest level of functional protein (48.8 mg/mL) and the highest specific activity (0.862 mg active α1 -PI per mg total protein). By size exclusion chromatography, Respreeza was 97.4% pure, followed by Alfalastin 88.1%, Prolastin 76.9%, and Trypsone 70.8%. By reversed phase chromatography, Respreeza had an α1 -PI purity of 97.7%, followed by Trypsone 88.0%, Prolastin 78.0%, and Alfalastin 69.5%. The main protein band by sodium dodecyl sulphate-polyacrylamide gel electrophoresis was found for all products at approximately 50 kDa. Additional protein bands were found for Prolastin, Alfalastin, and Trypsone. The α1 -PI products differed in cysteine oxidation state and C-terminal lysine status. α1 -PI products tested differ in purity, concentration, and chemical variation. Respreeza has the highest level of purity. The impact of the non-therapeutic proteins identified has not been evaluated.
- Is Part Of:
- Biologicals. Volume 50(2017)
- Journal:
- Biologicals
- Issue:
- Volume 50(2017)
- Issue Display:
- Volume 50, Issue 2017 (2017)
- Year:
- 2017
- Volume:
- 50
- Issue:
- 2017
- Issue Sort Value:
- 2017-0050-2017-0000
- Page Start:
- 63
- Page End:
- 72
- Publication Date:
- 2017-11
- Subjects:
- α1-antitrypsin -- α1-proteinase inhibitor -- Alfalastin -- Prolastin -- Respreeza -- Trypsone
Biological products -- Standards -- Periodicals
Biological Products -- Periodicals
Biological Products -- standards -- Periodicals
Produits biologiques -- Normes -- Périodiques
Biological products -- Standards
Periodicals
615.37 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10451056 ↗
http://www.elsevier.com/journals ↗
http://firstsearch.oclc.org/journal=1045-1056;screen=info;ECOIP ↗ - DOI:
- 10.1016/j.biologicals.2017.08.010 ↗
- Languages:
- English
- ISSNs:
- 1045-1056
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2081.670000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5401.xml